<DOC>
	<DOCNO>NCT01672983</DOCNO>
	<brief_summary>This study evaluate safety , tolerability , antiviral activity , pharmacokinetics ABT-450 ( also know paritaprevir ) ritonavir ( ABT-450/r ) ABT-267 ( also know ombitasvir ) adult Japanese patient chronic hepatitis C virus genotype 1b ( HCV GT1b ) genotype 2 ( HCV GT2 ) infection previous treat pegylated interferon/ribavirin ( pegIFN/RBV ) .</brief_summary>
	<brief_title>A Study Evaluate ABT-450 With Ritonavir ( ABT-450/r ) ABT-267 Japanese Adults With Chronic Hepatitis C Virus Infection</brief_title>
	<detailed_description>This multicenter , randomize , open-label , parallel-arm , combination treatment study consist Treatment Post-treatment Phase , divide 2 cohort : 1 ) chronic HCV GT1b- infect , pegIFN/RBV treatment-exposed Japanese adult ; 2 ) HCV GT2-infected , pegIFN/RBV treatment-exposed Japanese adult . The Treatment Phase evaluate antiviral activity , safety , pharmacokinetics range ABT-450/r ABT-267 dose 12 24 week . The Post-treatment Phase evaluate evolution persistence viral resistance ABT-267 ABT-450 .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<criteria>Females must practice specific form birth control study treatment , postmenopausal 2 year surgically sterile Chronic hepatitis C , genotype 1b ( HCVGT1b ) genotype 2 ( HCV GT2 ) infection ( HCV RNA level great 10,000 IU/mL screen ) previously treat pegylated interferon/ribavirin ( pegIFN/RBV ) . Subject 's hepatitis C virus genotype subgenotype 1b subject null responder partial responder , OR Subject 's hepatitis C virus genotype subgenotype 2 subject null responder , partial responder , relapser ( Null responder : receive least 10 week pegIFN/RBV treatment HCV fail achieve 2 log10 IU/mL reduction HCV RNA Week 12 ; Partial responder : receive least 20 week pegIFN/RBV treatment HCV achieve â‰¥ 2 log10 IU/mL reduction HCV RNA Week 12 , fail achieve HCV RNA undetectable ( HCV RNA &lt; low limit detection [ &lt; LLOD ] ) end treatment ; Relapsers : receive least 1 course pegIFN/RBV treatment HCV undetectable end treatment , HCV RNA detectable within 24 week treatment followup ) . Significant liver disease cause HCV primary cause Positive screen drug alcohol . Positive hepatitis B surface antigen antihuman immunodeficiency virus antibody . Use contraindicate medication within 2 week dose Previous use investigational commercially available antiHepatitis C virus agent pegIFN/RBV , include previous exposure ABT450 ABT267 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Japanese</keyword>
	<keyword>Hepatitis C</keyword>
	<keyword>Genotype 2</keyword>
	<keyword>Genotype 1b</keyword>
	<keyword>paritaprevir</keyword>
	<keyword>ombitasvir</keyword>
	<keyword>ritonavir</keyword>
	<keyword>VIEKIRAX Combination Tablets</keyword>
</DOC>